Compare NVG & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NVG | SUPN |
|---|---|---|
| Founded | 1999 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | N/A | 2012 |
| Metric | NVG | SUPN |
|---|---|---|
| Price | $12.53 | $51.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $61.60 |
| AVG Volume (30 Days) | 568.8K | ★ 636.6K |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 4.65% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $681,539,000.00 |
| Revenue This Year | N/A | $8.32 |
| Revenue Next Year | N/A | $23.36 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 4.54 |
| 52 Week Low | $9.68 | $29.16 |
| 52 Week High | $12.21 | $57.65 |
| Indicator | NVG | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 45.37 | 67.82 |
| Support Level | $12.42 | $51.01 |
| Resistance Level | $12.64 | $52.30 |
| Average True Range (ATR) | 0.08 | 1.49 |
| MACD | -0.02 | 0.65 |
| Stochastic Oscillator | 29.28 | 89.77 |
Nuveen AMT-Free Municipal Credit Income Fund is a diversified, closed-end management investment company. Its objective is to provide current income exempt from regular federal income tax and federal alternative minimum tax applicable to individuals and enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the investment adviser believes are underrated or undervalued or represent undervalued municipal market sectors.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.